Skip to content

Targets Matter

Making better cancer immunotherapies for patients, starting with better target discovery. That’s why we say #TargetsMatter.

ATLAS™ – a unique and proprietary discovery platform – designed to identify the right targets (antigens) of anti-tumor responses in any patient.

Our Pipeline

ATLAS drives Genocea’s pipeline of differentiated clinical stage immunotherapies.

GEN-011: Neoantigen adoptive T cell therapy

Phase 1/2a clinical trial in progress

GEN-009: Neoantigen vaccine

Differentiated Phase 1/2a immune responses, clinical responses

Learn more about our novel Inhibigens™ – T cells specific for these antigens suppress anti-tumor responses and drive tumor growth.

Chip Clark President and Chief Executive Officer
Chip Clark President and Chief Executive Officer

Chip has served as our President and Chief Executive Officer since February 2011 after serving as our Chief Business Officer from August 2010 to February 2011. Chip has also served on our board of directors since February 2011. Prior to joining Genocea, he served as Chief Business Officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004.

Prior to Vanda, Chip was a principal at Care Capital, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Fun Facts about Chip: is happiest when exploring with his wife and children; his favorite Twitter follows are Muppets.

Diantha Duvall Chief Financial Officer
Diantha Duvall Chief Financial Officer

Diantha joined Genocea in March 2019, bringing broad life science financial leadership experience to the company. Most recently, Diantha served as Vice President, Controller and Chief Accounting Officer at Bioverativ, Inc. Prior to Bioverativ, she served as U.S. and Global Commercial Controller at Biogen and held a number of positions as an Executive Director at Merck and Co. While at Merck, her experiences spanned roles in venture investment, business development, joint ventures, and alliances, as well as operational controls and technical accounting. In addition, she gained extensive experience in SEC reporting, Sarbanes Oxley compliance, transaction support and risk management while at PricewaterhouseCoopers. She received a bachelor’s degree in Economics and Public Policy from Colby College and masters’ degrees in both Accounting and Business Administration from Northeastern University. Diantha is also a Certified Public Accountant licensed in the state of Massachusetts.

Fun Facts about Diantha: enjoys traveling and skiing especially with her family and is an avid Boston sports fan.

Jessica Baker Flechtner, Ph.D. Chief Scientific Officer
Jessica Baker Flechtner, Ph.D. Chief Scientific Officer

Jess joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She is widely recognized as a pioneer in the development of novel vaccines directed toward T cell immunity and has more than 20 years of experience in immunology, cancer, infectious disease, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against cancer using the company’s proprietary ATLAS platform to identify and characterize both common and personalized antigens.

Prior to joining Genocea, Jess served in a variety of roles developing vaccines and immunotherapies for cancer, infectious disease, autoimmunity, and allergy at companies including Mojave Therapeutics and Antigenics (now Agenus). Jess received a B.S. in Animal Science and a Ph.D. in Cellular Immunology from Cornell University, and performed her post-doctoral work at Dana Farber Cancer Institute and Harvard Medical School. She is a member of Women in Bio, the American Association of Immunologists, the American Association for Cancer Research, the Society for Immunotherapy of Cancer, the President’s Council of Cornell Women, and the American Society for Microbiology. She is also an inventor on numerous pending and issued patents and is the author of multiple peer-reviewed scientific publications.

Fun Facts about Jess: can trace her roots back to the original U.S. colonies, is an avid skier, and, in fact, hates being hot and would be just fine living somewhere with year-round snow!

Raymond D. Stapleton, Ph.D. Chief Technology Officer
Raymond D. Stapleton, Ph.D. Chief Technology Officer

Ray joined Genocea in January 2021 bringing 20+ years of industry experience having led technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies. Most recently, Ray served as President and Chief Operating Officer of American Type Culture Collection (ATCC), and an Officer and member of the Board of Directors of both ATCC and ATCC Global. Ray brings extensive management experience to Genocea, including translational sciences, the application of Lean Six-Sigma management, and commercial launch of multiple billion-dollar biologic, vaccine, and small molecule products.

Prior to ATCC, Ray worked in senior manufacturing and technical operations roles at Iovance Biotherapeutics, Inc. and Synthetic Biologics, Inc. after spending 15 years in areas of increasing responsibility in Merck and Company, Inc.’s manufacturing organization.  At Merck, Ray lead a complex science, technology, and engineering organization at a manufacturing site responsible for supporting Merck’s $5 billion vaccine business.

Ray earned a bachelor’s degree in Biology from Mary Washington College in Fredericksburg, Virginia and received his PhD in Microbial Ecology from the University of Tennessee, Knoxville. He has served as peer reviewer for a half dozen scientific journals, co-authored 17 peer-reviewed manuscripts, as well as multiple patents.

Fun Facts about Ray: Ray enjoys outdoor activities including cycling, mountain biking, swimming, and participating in triathlons (though running is his least favorite part of the race!).

Jacquelyn Sumer Chief Legal and Compliance Officer
Jacquelyn Sumer Chief Legal and Compliance Officer

Jackie joined Genocea in February 2021 as Chief Legal and Compliance Officer.  Jackie brings over 15 years of legal and strategic leadership experience.  Most recently Jackie served as Vice President, Assistant General Counsel at Bristol-Myers Squibb, where she led the Worldwide Hematology and Cell Therapy legal team.  Previously Jackie led Celgene Corporation’s CAR T legal team, supporting clinical development and launch preparedness for therapies in development.  Prior to her time at Celgene, Jackie held positions of increasing responsibility at Novartis Oncology and Novartis Pharmaceuticals Corporation where she advised on a wide array of matters relating to pre-clinical and clinical development, commercialization and market access, employment, litigation and government investigations, and compliance.

Jackie began her legal career at Kaye Scholer, LLP and clerked for the Honorable Gladys Kessler of the United States District Court in Washington, D.C.  She holds a J.D. and Master of Laws in international and comparative law from Duke University School of Law and a B.A. from Bucknell University.

Fun Fact about Jackie:  Jackie enjoys practicing yoga and boxing, and does not find the two to be contradictory.


May 24, 2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, Read More >

April 28, 2022

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, Read More >

April 8, 2022

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

     GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and Read More >